Search bioRxiv⌕ Search

Biology subjects

Liefwalker, D.

Publications and source records attributed to Liefwalker, D..

2 recordsLinked to original sources

KDM5B expression is suppressed by MYC in a negative feedback loop to promote cell survival.

Both c-MYC and KDM5B are global regulators of gene transcription, cell identity, and master transcription factors in hematopoietic malignancies. In this study we link these two critical factors in a negative feedback loop that controls apoptosis and cell survival. We find the MYC specifically downregulates KDM5B, thereby inhibiting its transcriptional repressive functions. Loss of KDM5B abrogates the cell death response to MYC withdrawal in MYC-dependent cells, indicating KDM5B mediates cell death. We find that KDM5B regulates the MYC network, and specifically demethylates the MYC locus. In summary we have discovered a negative feedback loop between MYC and KDM5B. The MYC-dependent suppression of KDM5B leads to a global increase in H3K4me3 methylation, transcriptional activity, and increase cell survival and tumor progression.

cancer biology↗

MYC Functions as a Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies

The MYC oncogene drives T and B lymphoid malignancies, including Burkitts lymphoma (BL) and Acute Lymphoblastic Leukemia (ALL). Using CyTOF, we demonstrate a systemic reduction in natural killer (NK) cell-mediated surveillance in SR-tTA/Tet-O-MYCON mice bearing MYC-driven T-lymphomas, due to an arrest in NK cell maturation. Inactivation of lymphoma-intrinsic MYC releases the brakes on NK maturation restoring NK homeostasis. Lymphoma-intrinsic MYC arrests NK maturation by transcriptionally repressing STAT1/2 and secretion of Type I Interferons (IFNs). Treating T-lymphoma-bearing mice with Type I IFN improves survival by rescuing NK cell maturation. In MYC-driven BL patients, low expression of both STAT1 and STAT2 correlates significantly with the absence of activated NK cells and predicts unfavorable clinical outcomes. Adoptive transfer of mature NK cells is sufficient to delay both T-lymphoma growth and recurrence post MYC inactivation. Our studies thus provide a rationale for developing NK cell-based therapies to effectively treat MYC-driven lymphomas in the future.\n\nAbbreviations

cancer biology↗